ECSP11011479A - Compuestos heterocíclicos de fenoximetilo - Google Patents

Compuestos heterocíclicos de fenoximetilo

Info

Publication number
ECSP11011479A
ECSP11011479A EC2011011479A ECSP11011479A ECSP11011479A EC SP11011479 A ECSP11011479 A EC SP11011479A EC 2011011479 A EC2011011479 A EC 2011011479A EC SP11011479 A ECSP11011479 A EC SP11011479A EC SP11011479 A ECSP11011479 A EC SP11011479A
Authority
EC
Ecuador
Prior art keywords
compounds
fenoximetilo
heterocyclic
phenoxymethyl
phosphodiesterase
Prior art date
Application number
EC2011011479A
Other languages
English (en)
Inventor
Richard Chesworth
Gideon Shapiro
Amy Ripka
Original Assignee
En Vivo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by En Vivo Pharmaceuticals Inc filed Critical En Vivo Pharmaceuticals Inc
Publication of ECSP11011479A publication Critical patent/ECSP11011479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos de fenoximetilo que inhiben al menos una fosfodiesterasa 10 como composiciones farmacéuticas que contienen tales compuestos y métodos para tratar diversos trastornos del SNC mediante la administración de tales compuestos a un paciente que lo necesita
EC2011011479A 2009-05-07 2011-11-24 Compuestos heterocíclicos de fenoximetilo ECSP11011479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17641309P 2009-05-07 2009-05-07
PCT/US2009/068644 WO2010128995A1 (en) 2009-05-07 2009-12-18 Phenoxymethyl heterocyclic compounds

Publications (1)

Publication Number Publication Date
ECSP11011479A true ECSP11011479A (es) 2011-12-30

Family

ID=41549054

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011479A ECSP11011479A (es) 2009-05-07 2011-11-24 Compuestos heterocíclicos de fenoximetilo

Country Status (32)

Country Link
US (3) US8343973B2 (es)
EP (3) EP2617420B1 (es)
JP (2) JP5628902B2 (es)
KR (1) KR101662699B1 (es)
CN (2) CN105125547A (es)
AU (1) AU2009345802B2 (es)
BR (1) BRPI0924617A8 (es)
CA (1) CA2761032A1 (es)
CL (1) CL2011002792A1 (es)
CO (1) CO6460744A2 (es)
CR (1) CR20110648A (es)
DK (2) DK2427454T3 (es)
EC (1) ECSP11011479A (es)
ES (2) ES2554788T3 (es)
HR (2) HRP20130482T1 (es)
HU (1) HUE026238T2 (es)
IL (2) IL216149A (es)
ME (1) ME02375B (es)
MX (1) MX2011011755A (es)
MY (1) MY183910A (es)
NZ (1) NZ596753A (es)
PE (1) PE20120900A1 (es)
PH (1) PH12013501321A1 (es)
PL (2) PL2617420T3 (es)
PT (2) PT2427454E (es)
RS (2) RS54529B1 (es)
RU (1) RU2531274C2 (es)
SG (1) SG175900A1 (es)
SI (2) SI2427454T1 (es)
SM (2) SMT201300070B (es)
WO (1) WO2010128995A1 (es)
ZA (1) ZA201108920B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
CA2761032A1 (en) 2009-05-07 2010-11-11 Envivo Pharmaceuticals, Inc. Phenoxymethyl heterocyclic compounds
MX2013009575A (es) 2011-02-18 2014-10-14 Exonhit Therapeutics Sa Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a).
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2260009C2 (ru) * 1999-11-05 2005-09-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) Новые гетероциклические соединения и их применение в качестве лекарственных средств
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20060111368A1 (en) 2002-06-26 2006-05-25 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
EA012211B1 (ru) 2005-01-07 2009-08-28 Пфайзер Продактс Инк. Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
JP2009535394A (ja) * 2006-05-02 2009-10-01 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
CA2761032A1 (en) 2009-05-07 2010-11-11 Envivo Pharmaceuticals, Inc. Phenoxymethyl heterocyclic compounds
US8614234B2 (en) * 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators
ES2879314T3 (es) * 2010-08-18 2021-11-22 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina

Also Published As

Publication number Publication date
RU2011149637A (ru) 2013-06-20
IL216149A0 (en) 2012-01-31
RS52838B (sr) 2013-10-31
PH12013501321B1 (en) 2014-08-27
HRP20130482T1 (en) 2013-08-31
PH12013501321A1 (en) 2014-08-27
NZ596753A (en) 2013-09-27
ME02375B (me) 2016-06-20
AU2009345802B2 (en) 2016-05-26
EP3020716A1 (en) 2016-05-18
MY183910A (en) 2021-03-17
IL244059A0 (en) 2016-04-21
SMT201300070B (it) 2013-09-06
SMT201600031B (it) 2016-02-25
PT2617420E (pt) 2015-12-18
CR20110648A (es) 2012-03-28
CL2011002792A1 (es) 2012-06-01
EP2427454B1 (en) 2013-03-20
JP2012526107A (ja) 2012-10-25
PT2427454E (pt) 2013-06-20
US20130143888A1 (en) 2013-06-06
KR101662699B1 (ko) 2016-10-05
AU2009345802A1 (en) 2011-12-15
RS54529B1 (sr) 2016-06-30
PL2617420T3 (pl) 2016-04-29
MX2011011755A (es) 2012-03-16
DK2617420T3 (da) 2015-12-07
HK1186981A1 (en) 2014-03-28
HRP20151273T1 (hr) 2016-01-29
ES2409404T3 (es) 2013-06-26
EP2617420B1 (en) 2015-09-23
CN102459242B (zh) 2015-08-26
CA2761032A1 (en) 2010-11-11
SG175900A1 (en) 2011-12-29
HUE026238T2 (en) 2016-06-28
ES2554788T3 (es) 2015-12-23
PE20120900A1 (es) 2012-08-14
WO2010128995A1 (en) 2010-11-11
BRPI0924617A2 (es) 2017-07-11
HK1167402A1 (en) 2012-11-30
US20150322069A1 (en) 2015-11-12
US20100292238A1 (en) 2010-11-18
EP2427454A1 (en) 2012-03-14
JP5943053B2 (ja) 2016-06-29
CO6460744A2 (es) 2012-06-15
ZA201108920B (en) 2012-08-29
PL2427454T3 (pl) 2013-09-30
US8343973B2 (en) 2013-01-01
IL216149A (en) 2016-02-29
BRPI0924617A8 (pt) 2017-10-03
SI2427454T1 (sl) 2013-08-30
US8946222B2 (en) 2015-02-03
JP2015038112A (ja) 2015-02-26
JP5628902B2 (ja) 2014-11-19
EP2617420A1 (en) 2013-07-24
SI2617420T1 (sl) 2016-02-29
KR20120027268A (ko) 2012-03-21
CN102459242A (zh) 2012-05-16
CN105125547A (zh) 2015-12-09
RU2531274C2 (ru) 2014-10-20
DK2427454T3 (da) 2013-06-17

Similar Documents

Publication Publication Date Title
CO6460744A2 (es) Compuestos heterocíclicos de fenoximetilo
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
UA124922C2 (uk) Модулятори ядерного транспорту та їх застосування
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
MX344530B (es) Compuestos de benceno substituido.
PH12015500825B1 (en) Substituted benzene compounds
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
NI201400134A (es) Novedosas n - piridinil amidas cíclicas sustituidas como inhibidores de quinasa.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
CO6741154A2 (es) Compuestos de triazolopiridina
PE20150709A1 (es) Benzamidas
MX394356B (es) Métodos y composiciones para tratar hiperhidrosis.
PE20142318A1 (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
NZ706865A (en) Solid form of dihydro-pyrido-oxazine derivative
UY32679A (es) Antagonistas policíclicos de receptores de ácido lisofosfatidico
CU20140134A7 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa